# DARPA Awards $8.3M CoagCare Contract

DARPA has awarded Abram Scientific a contract worth up to **$8.3 million** to advance its CoagCare point-of-care blood coagulation diagnostic toward FDA clearance. The work includes adapting the system for shelf-stable blood analogue components, establishing manufacturing capabilities, and developing a military-focused system. Contract terms and the factors determining the final amount awarded were not disclosed. DARPA also provided $2 million in October 2025 to support CoagCare miniaturization.

- The effort links medical-device development with defense needs for coagulation diagnostics and shelf-stable blood-related components; companies with relevant diagnostic, manufacturing, and military medical capabilities may find this a useful indicator of agency priorities.
- Abram Scientific’s work spans product development, manufacturing readiness, and progress toward FDA clearance, highlighting the multiple technical and regulatory workstreams involved in transitioning a diagnostic for military use.
- The award is a development effort, not an announced open solicitation. The undisclosed contract terms mean the available information does not establish the final award amount or specific follow-on procurement plans.

**Jurisdictions:** federal
**Industries:** Healthcare, Defense & Military
**Topics:** Regulatory Compliance
**Published:** October 13, 2026

### Government Entities
- Defense Advanced Research Projects Agency (DARPA)
- U.S. Department of Defense (DoD)
- U.S. Food and Drug Administration (FDA)

### Vendors
- Abram Scientific (awardee)

### Sources
- [Abram snags $8.3M US DoD contract to advance blood coagulation diagnostic - Medical Device Network](https://www.medicaldevice-network.com/news/abram-snags-8-us-dod-contract-to-advance-blood-coagulation-diagnostic) - Medical Device Network